Advertisement
KROS vs MGTX
Which Stock Would AI Choose? Keros Therapeutics (KROS) vs. MeiraGTx Holdings (MGTX) Stock Comparison
Key Takeaways
- Keros Therapeutics (KROS) is a clinical-stage biopharma focused on TGF-β (transforming growth factor-beta) protein therapeutics, while MeiraGTx Holdings (MGTX) is a clinical-stage genetic medicines (gene therapy) company.
- Both companies remain largely pre-commercial, but their recent market positioning has diverged sharply: MGTX has gained roughly 30% over the past year, while KROS has fallen close to 50% year to date.
- KROS leans heavily on its partnered elritercept program and its wholly owned rinvatercept candidate, whereas MGTX has a broader late-stage gene therapy pipeline and recently reacquired full rights to its bota-vec program.
- Analyst sentiment is notably stronger for MGTX, with a consensus "Buy" rating and a price target far above the current share price, versus a more mixed, neutral-leaning view on KROS.
- Both names carry elevated clinical and financing risk typical of development-stage biotech, making trend consistency and catalyst timing central to any AI-driven assessment.
Introduction
Investors comparing small-cap biotechnology stocks often face a choice between pipeline depth, financing strength, and near-term momentum. KROS and MGTX illustrate this trade-off well. One is a TGF-β-focused biopharmaceutical company repositioning around a single lead asset; the other is a vertically integrated genetic medicines firm advancing multiple late-stage programs. This stock comparison is most relevant to traders and investors who follow clinical-stage healthcare names and want to understand how relative performance, market positioning, and catalyst schedules differ between two pre-revenue companies with very different recent trajectories.
KROS Overview and Recent Performance
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics that target dysfunctional signaling in the TGF-β family of proteins, which regulate tissue growth and repair. Its most advanced candidate, elritercept, is partnered with Takeda for the treatment of cytopenias such as anemia and thrombocytopenia in myelodysplastic syndromes (MDS, a group of blood disorders) and myelofibrosis. Its wholly owned lead candidate, rinvatercept, is being developed for Duchenne muscular dystrophy (DMD, a progressive muscle-wasting disease) and amyotrophic lateral sclerosis (ALS, a neurodegenerative condition).
Recent market activity has been challenging for KROS. The company has no marketed products, and its revenue is tied to irregular collaboration and milestone payments rather than recurring product sales. In recent quarters, reported revenue fell to near zero, and losses widened versus consensus estimates. The stock has declined sharply in recent weeks and is down close to 50% year to date. Positive catalysts have included a $20 million milestone from Takeda tied to a Phase 3 study and the initiation of a Phase 2 trial for rinvatercept in DMD, but these have not yet reversed negative sentiment. Cash of roughly $257 million is expected to fund operations into the first half of 2028.
MGTX Overview and Recent Performance
MeiraGTx Holdings is a clinical-stage genetic medicines company with a vertically integrated manufacturing platform. Its pipeline spans ocular, neurodegenerative, and salivary gland diseases, including bota-vec for X-linked retinitis pigmentosa (XLRP, an inherited retinal disease), AAV2-hAQP1 for radiation-induced xerostomia (chronic dry mouth), and AAV-GAD for Parkinson's disease. The company recently reacquired full rights to bota-vec from Johnson & Johnson and has secured backing from partners including Sanofi.
MGTX has delivered stronger relative performance over the past year, gaining roughly 30%, though shares pulled back in recent weeks. Momentum has been supported by regulatory designations, including a Breakthrough Therapy Designation for AAV2-hAQP1 and a Regenerative Medicine Advanced Therapy (RMAT) designation for its Parkinson's program, along with positive multi-year clinical data. Financial results remain uneven, with a wider-than-expected quarterly loss earlier in the year, but the company has also reported a shift toward profitability in more recent periods. Analysts maintain a consensus "Buy" rating, with an average price target well above the current price.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's most relevant AI trading bots for current market conditions. Tickeron maintains hundreds of AI Trading Bots that trade thousands of different tickers, but only the best-performing and most suitable strategies earn a place in this featured section—currently highlighting a handful of top bots selected from a much larger total universe. Each bot operates with its own trading style, strategy, timeframe, performance record, and set of tickers, giving traders a range of approaches to evaluate. These bots publish statistics such as realized return, win rate, and profit factor, helping users assess suitability before subscribing. Explore the Trending AI Robots page to see which strategies are currently aligned with the market.
Head-to-Head Comparison
The two companies differ most in pipeline breadth and recent momentum. KROS has effectively concentrated its value proposition on rinvatercept after transitioning elritercept costs to Takeda, which reduces near-term burn but increases dependence on a single unproven asset. MGTX, by contrast, maintains multiple late-stage programs and a manufacturing footprint that offers more optionality, though it also carries greater operational complexity and a history of shareholder dilution.
On momentum, MGTX has the stronger trend, with positive year-over-year returns and constructive analyst coverage. KROS has lagged materially, weighed down by revenue visibility concerns and a premium valuation relative to its uncertain near-term catalysts. In terms of risk, both face clinical execution risk, but KROS's reliance on a single lead candidate and uneven collaboration income creates a more concentrated risk profile. Sector exposure is similar—both are development-stage biotech—but their growth drivers are distinct: KROS is anchored to muscle and blood disorders, while MGTX spans gene therapy across retinal, neurological, and salivary indications.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalyst breadth, and relative positioning, Tickeron's AI would currently lean toward MGTX. The stock's stronger trailing momentum, broader late-stage pipeline, and more favorable analyst consensus suggest a comparatively more constructive setup than KROS, whose negative year-to-date trend and concentrated single-asset risk create a less stable profile. That said, this assessment is probabilistic rather than definitive: KROS's cash runway and upcoming clinical data could shift positioning quickly, while MGTX's recent pullback and financing history introduce their own volatility. Both names warrant ongoing monitoring for catalyst-driven trend changes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and MGTX is a Hold.
KROS's Indicator enters downward trend
The Aroon Indicator for KROS entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator formed such a pattern. In 166 of the 196 cases the stock moved lower. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KROS as a result. In 68 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for KROS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 31 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
KROS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 225 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
KROS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.498). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. KROS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MGTX sees its Stochastic Oscillator recovers from oversold territory
On November 09, 2026, the Stochastic Oscillator for MGTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 67 instances where the indicator left the oversold zone. In 61 of the 67 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MGTX's RSI Oscillator exited the oversold zone, 22 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MGTX as a result. In 79 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for MGTX just turned positive on October 21, 2026. Looking at past instances where MGTX's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +6.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGTX advanced for three days, in 213 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
MGTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for MGTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. MGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.010) is normal, around the industry mean (3.498). P/E Ratio (10.112) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.715) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KROS | MGTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 95 | 16 | |
PRICE GROWTH RATING 1..100 | 78 | 62 | |
P/E GROWTH RATING 1..100 | 98 | 78 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KROS's Valuation (26) in the null industry is somewhat better than the same rating for MGTX (83) in the Biotechnology industry. This means that KROS’s stock grew somewhat faster than MGTX’s over the last 12 months.
KROS's Profit vs Risk Rating (100) in the null industry is in the same range as MGTX (100) in the Biotechnology industry. This means that KROS’s stock grew similarly to MGTX’s over the last 12 months.
MGTX's SMR Rating (16) in the Biotechnology industry is significantly better than the same rating for KROS (95) in the null industry. This means that MGTX’s stock grew significantly faster than KROS’s over the last 12 months.
MGTX's Price Growth Rating (62) in the Biotechnology industry is in the same range as KROS (78) in the null industry. This means that MGTX’s stock grew similarly to KROS’s over the last 12 months.
MGTX's P/E Growth Rating (78) in the Biotechnology industry is in the same range as KROS (98) in the null industry. This means that MGTX’s stock grew similarly to KROS’s over the last 12 months.
| KROS | MGTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 82% |
| Advances ODDS (%) | 15 days ago 77% | 1 day ago 83% |
| Declines ODDS (%) | 3 days ago 75% | 7 days ago 83% |
| BollingerBands ODDS (%) | 1 day ago 77% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KROS’s FA Score shows that 1 FA rating(s) are green while MGTX’s FA Score has 1 green FA rating(s).
- KROS’s FA Score: 1 green, 4 red.
- MGTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KROS’s TA Score shows that 4 TA indicator(s) are bullish while MGTX’s TA Score has 6 bullish TA indicator(s).
- KROS’s TA Score: 4 bullish, 6 bearish.
- MGTX’s TA Score: 6 bullish, 2 bearish.
Price Growth
KROS (@Biotechnology) experienced а -13.85% price change this week, while MGTX (@Biotechnology) price change was +1.05% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.36%. For the same industry, the average monthly price growth was -9.96%, and the average quarterly price growth was +79.71%.
Reported Earning Dates
KROS is expected to report earnings on Mar 03, 2027.
MGTX is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KROS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with SANA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then SANA could also see price increases.
| Ticker / NAME | Correlation To KROS | 1D Price Change % | ||
|---|---|---|---|---|
| KROS | 100% | +1.74% | ||
| SANA - KROS | 50% Loosely correlated | -1.42% | ||
| IMNM - KROS | 46% Loosely correlated | -3.67% | ||
| ARVN - KROS | 45% Loosely correlated | +2.37% | ||
| LXEO - KROS | 45% Loosely correlated | -2.55% | ||
| MGTX - KROS | 45% Loosely correlated | +1.37% | ||
More | ||||
MGTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MGTX has been loosely correlated with EDIT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if MGTX jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To MGTX | 1D Price Change % | ||
|---|---|---|---|---|
| MGTX | 100% | +1.37% | ||
| EDIT - MGTX | 58% Loosely correlated | -8.91% | ||
| SANA - MGTX | 55% Loosely correlated | -1.42% | ||
| KURA - MGTX | 53% Loosely correlated | N/A | ||
| VYGR - MGTX | 51% Loosely correlated | -8.29% | ||
| TSHA - MGTX | 51% Loosely correlated | -2.17% | ||
More | ||||